Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers: Results from a ...
Prof Bob Li talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase II trial that examined the clinical activity of ado-trastuzumab emtansine in patients with HER2-amplified salivary gland cancer.
He reports that a 90 percent response rate was achieved in these patients. Overall, The drug also demonstrated a durable efficacy and was well-tolerated. Biomarkers for HER2-amplification were also well correlated with FISH and immunohistochemistry.
Prof Li mentions that further work will focus on improving the biomarkers, which includes looking into cell-free DNA, acquired resistance mechanisms and dimerisation assays.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps
-
Category
No comments found